Cytosorbents Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	6.25	3.28	14.13	22.14	52.14
Cash & Short-Term Investments	6.25	3.28	14.13	22.14	52.14
Cash Growth	90.52%	-76.79%	-36.19%	-57.53%	-27.00%
Accounts Receivable	7.55	7.32	6.06	5.66	4.52
Inventory	5.28	2.73	3.38	3.46	4.77
Other Current Assets	1.55	8.27	1.83	2.49	2.87
Total Current Assets	20.63	21.6	25.4	33.76	64.3
Net Property, Plant & Equipment	18.75	20.51	22.12	23.35	18.57
Other Intangible Assets	3.23	-	-	-	-
Other Long-Term Assets	1.58	5.26	5.44	6.12	6.65
Total Assets	44.18	47.37	52.96	63.23	89.52
Accounts Payable	2.87	3.34	3.8	1.66	2.81
Accrued Expenses	6.3	6.03	7.36	7.95	10.31
Current Portion of Long-Term Debt	-	-	2.5	-	-
Current Portion of Leases	0.54	0.45	0.37	0.11	0.57
Total Current Liabilities	9.71	9.83	14.04	9.71	13.69
Long-Term Debt	16.67	14	2.54	5	-
Long-Term Leases	11.9	12.44	12.9	13.14	13.25
Total Long-Term Liabilities	28.57	26.44	15.44	18.14	13.25
Total Liabilities	38.28	36.27	29.48	27.86	26.94
Common Stock	0.06	0.06	0.05	0.04	0.04
Additional Paid-in Capital	321.02	310.81	306.19	287	283.19
Accumulated Other Comprehensive Income	-2.98	4.25	0.53	2.33	0.53
Retained Earnings	-312.21	-304.01	-283.29	-254	-221.19
Shareholders' Equity	5.9	11.11	23.48	35.37	62.58
Total Liabilities & Equity	44.18	47.37	52.96	63.23	89.52
Total Debt	29.11	26.89	18.31	18.25	13.82
Net Cash (Debt)	-22.86	-23.61	-4.18	3.89	38.32
Net Cash Growth	-	-	-	-89.84%	-45.57%
Net Cash Per Share	-0.37	-0.43	-0.09	0.09	0.88
Book Value	5.9	11.11	23.48	35.37	62.58
Book Value Per Share	0.09	0.20	0.53	0.81	1.44
Tangible Book Value	2.68	11.11	23.48	35.37	62.58
Tangible Book Value Per Share	0.04	0.20	0.53	0.81	1.44

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q